Pfizer Inc. (NYSE:PFE) Holdings Cut by Guyasuta Investment Advisors Inc.

Guyasuta Investment Advisors Inc. decreased its stake in Pfizer Inc. (NYSE:PFE) by 69.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 272,041 shares of the biopharmaceutical company’s stock after selling 622,742 shares during the quarter. Guyasuta Investment Advisors Inc.’s holdings in Pfizer were worth $7,832,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. MCF Advisors LLC raised its holdings in shares of Pfizer by 3.7% during the 3rd quarter. MCF Advisors LLC now owns 27,590 shares of the biopharmaceutical company’s stock valued at $915,000 after purchasing an additional 975 shares in the last quarter. U.S. Capital Wealth Advisors LLC raised its holdings in shares of Pfizer by 18.5% during the 3rd quarter. U.S. Capital Wealth Advisors LLC now owns 503,170 shares of the biopharmaceutical company’s stock valued at $16,690,000 after purchasing an additional 78,421 shares in the last quarter. Trust Co. of Toledo NA OH raised its holdings in shares of Pfizer by 2.1% during the 3rd quarter. Trust Co. of Toledo NA OH now owns 122,829 shares of the biopharmaceutical company’s stock valued at $4,074,000 after purchasing an additional 2,567 shares in the last quarter. JGP Wealth Management LLC raised its holdings in shares of Pfizer by 3.4% during the 3rd quarter. JGP Wealth Management LLC now owns 60,487 shares of the biopharmaceutical company’s stock valued at $2,006,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Blossom Wealth Management raised its holdings in shares of Pfizer by 11.5% during the 3rd quarter. Blossom Wealth Management now owns 10,943 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 1,130 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 1.2 %

Shares of NYSE:PFE traded up $0.31 during trading on Monday, hitting $25.71. 13,964,395 shares of the company’s stock were exchanged, compared to its average volume of 41,667,207. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $40.37. The firm has a 50-day moving average price of $26.96 and a two-hundred day moving average price of $28.36. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The firm has a market cap of $145.58 billion, a P/E ratio of 71.44, a PEG ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the previous year, the company earned $1.14 EPS. Pfizer’s revenue was down 41.3% on a year-over-year basis. Equities analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.53%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s payout ratio is presently 466.67%.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent research reports. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Eleven analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.